Research & Development
Colorectal Cancer: Page 2
Personalis to collaborate with UCSF on colorectal cancer treatment study
The study will use the Next Personal assay to evaluate circulating tumor DNA (ctDNA)-based signatures associated with treatment response and adverse events in a cohort of patients with late-stage CRC who are receiving a combination therapy.
November 30, 2022
Universal Diagnostics study assesses methylation biomarkers' role in early colorectal cancer
The company will present the findings at the AACR Special Conference on Precisions, Prevention, Early Detection, and Interception of Cancer being held in Austin, TX, November 17-19.
November 17, 2022
Mainz Biomed initiates U.S. extension of colorectal cancer study to evaluate mRNA biomarkers
Mainz Biomed announced an extension of its ColoFuture European study, which aims to evaluate the use of mRNA biomarkers for the early detection of colorectal cancer.
November 15, 2022
Nucleai to present data on multiplex immunofluorescence analysis for colorectal cancer research
Nucleai will present data this week demonstrating the capability of multiplex immunofluorescence analysis to correlate spatial features with patient outcomes in colorectal cancer.
November 7, 2022
Exact Sciences shares rise with 15% growth in Q3 revenues
Screening segment revenue, including sales for the Cologuard colon cancer molecular test, was $360.8 million, an increase of 29% year-over-year.
November 4, 2022
Exact Sciences to present data on positive impact of Cologuard
The firm said it will present data supporting the positive impact of its Cologuard molecular colorectal cancer screening tool during the American College of Gastroenterology Annual Meeting.
October 24, 2022
Exact Sciences awards $525K in grants to improve CRC screening
Exact's Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) program provided the grant funding. Awardees will use the funds to implement evidence-based and informed intervention strategies proven to increase colorectal cancer screening rates, the firm said.
September 21, 2022
Natera presents colorectal, breast cancer data at ESMO 2022
One abstract, related to the Bellini trial, examined the potential clinical utility of circulating tumor DNA (ctDNA) in assessing the response to neoadjuvant immunotherapy in patients with early-stage (I-II) triple-negative breast cancer (TNBC).
September 12, 2022
Indica Labs, iCAIRD partner on AI for colon cancer
Using anonymized hematoxylin and eosin (H&E) slides from the National Health Service Greater Glasgow and Clyde (NHSGGC) digital pathology archive, Indica and iCAIRD will collaboratively train, validate, and test the algorithm, which will be designed to detect cancer within lymph nodes from colorectal surgery cases.
August 29, 2022
Geneoscopy wraps up enrollment for colorectal cancer trial
The pivotal trial will assess the ability of the company's at-home, noninvasive test for detecting colorectal cancer and advanced adenomas in average-risk individuals.
August 22, 2022
CMS extends Signatera molecular disease test coverage
The decision took effect in April, and adds to existing Medicare coverage for the test for colorectal cancer and for pan-cancer immunotherapy monitoring, the company said.
July 17, 2022
Exact Sciences supports CMS screening policy changes
The CMS Calendar Year 2023 Physician Fee Schedule proposal considers follow-up colonoscopy to an at-home test as a preventative service. The rule would eliminate all costs to Medicare patients for a follow-up colonoscopy following a positive at-home colorectal cancer screening test.
July 10, 2022
Page 2 of 5